PL2104674T3 - Analogi tiofenu do leczenia lub zapobiegania zakażeniom flawiwirusowym - Google Patents

Analogi tiofenu do leczenia lub zapobiegania zakażeniom flawiwirusowym

Info

Publication number
PL2104674T3
PL2104674T3 PL07845534T PL07845534T PL2104674T3 PL 2104674 T3 PL2104674 T3 PL 2104674T3 PL 07845534 T PL07845534 T PL 07845534T PL 07845534 T PL07845534 T PL 07845534T PL 2104674 T3 PL2104674 T3 PL 2104674T3
Authority
PL
Poland
Prior art keywords
prevention
treatment
flavivirus infections
thiophene analogues
thiophene
Prior art date
Application number
PL07845534T
Other languages
English (en)
Inventor
Chun Kong Laval Chan
Das Sanjoy Kumar
Carl Poisson
Constantin G Yannopoulos
Guy Falardeau
Louis Vaillancourt
RéAL DENIS
Original Assignee
Vertex Pharmaceuticals Canada Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Canada Incorporated filed Critical Vertex Pharmaceuticals Canada Incorporated
Publication of PL2104674T3 publication Critical patent/PL2104674T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07845534T 2006-11-15 2007-11-15 Analogi tiofenu do leczenia lub zapobiegania zakażeniom flawiwirusowym PL2104674T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85893906P 2006-11-15 2006-11-15
EP07845534.2A EP2104674B8 (en) 2006-11-15 2007-11-15 Thiophene analogues for the treatment or prevention of flavivirus infections
PCT/CA2007/002064 WO2008058393A1 (en) 2006-11-15 2007-11-15 Thiophene analogues for the treatment or prevention of flavivirus infections

Publications (1)

Publication Number Publication Date
PL2104674T3 true PL2104674T3 (pl) 2013-12-31

Family

ID=39401287

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07845534T PL2104674T3 (pl) 2006-11-15 2007-11-15 Analogi tiofenu do leczenia lub zapobiegania zakażeniom flawiwirusowym

Country Status (25)

Country Link
US (3) US8003685B2 (pl)
EP (3) EP2104674B8 (pl)
JP (2) JP5290186B2 (pl)
KR (1) KR20090086081A (pl)
CN (3) CN102250074A (pl)
AP (1) AP2579A (pl)
AU (1) AU2007321677B2 (pl)
BR (1) BRPI0718915A2 (pl)
CA (1) CA2670260A1 (pl)
CO (1) CO6180430A2 (pl)
DK (1) DK2104674T3 (pl)
EA (2) EA201101492A1 (pl)
EC (1) ECSP099319A (pl)
ES (1) ES2423219T3 (pl)
HR (1) HRP20130658T1 (pl)
IL (1) IL198751A0 (pl)
MX (1) MX2009005185A (pl)
NO (1) NO20092038L (pl)
NZ (2) NZ596922A (pl)
PL (1) PL2104674T3 (pl)
PT (1) PT2104674E (pl)
RS (1) RS52874B (pl)
SG (1) SG176488A1 (pl)
SI (1) SI2104674T1 (pl)
WO (1) WO2008058393A1 (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0610283A2 (pt) 2005-05-13 2010-10-19 Virochem Pharma Inc composto, uso do mesmo na preparação de um medicamento para o tratamento ou prevenção de uma infecção por vìrus de hepatite c, composição farmacêutica e combinação farmacêutica
WO2010033226A1 (en) * 2008-09-17 2010-03-25 Nektar Therapeutics Oligomer-protease inhibitor conjugates
WO2010065668A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2011011303A1 (en) * 2009-07-21 2011-01-27 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
ES2559437T3 (es) * 2009-09-09 2016-02-12 Gilead Sciences, Inc. Inhibidores de virus de la familia Flaviviridae
JP2013512247A (ja) * 2009-11-25 2013-04-11 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染症の治療または予防のための５−アルキニル−チオフェン−２−カルボン酸誘導体およびそれらの使用
AU2010333656B2 (en) * 2009-12-18 2015-08-27 Boehringer Ingelheim International Gmbh HCV combination therapy
AP3576A (en) 2010-01-15 2016-02-08 Gilead Sciences Inc Inhibitors of flaviviridae viruses
CA2785563C (en) * 2010-01-15 2019-05-14 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
AU2011210795A1 (en) * 2010-01-29 2012-08-02 Vertex Pharmaceuticals Incorporated Therapies for treating Hepatitis C virus infection
WO2011150243A1 (en) * 2010-05-28 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2011159826A2 (en) 2010-06-15 2011-12-22 Vertex Pharmaceuticals Incorporated Hcv ns5b protease mutants
EP2585448A1 (en) 2010-06-28 2013-05-01 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
WO2012006070A1 (en) * 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
AU2011276526A1 (en) 2010-06-28 2013-01-10 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
EP2595983A1 (en) * 2010-07-22 2013-05-29 Novartis AG 2,3,5-trisubstituted thiophene compounds and uses thereof
AU2011292040A1 (en) 2010-08-17 2013-03-07 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of Flaviviridae viral infections
WO2012040389A2 (en) 2010-09-22 2012-03-29 Presidio Pharmaceuticals, Inc. Substituted bicyclic hcv inhibitors
EP2651906A4 (en) * 2010-12-17 2014-06-25 Cocrystal Discovery Inc INHIBITORS OF HEPATITIS C VIRUS POLYMERASE
WO2013009678A2 (en) * 2011-07-08 2013-01-17 Indiana University Research And Technology Corporation Compositions and methods for the treatment of norovirus infection
AU2012280959B2 (en) 2011-07-13 2015-08-06 Gilead Sciences, Inc. Thiophen-2-carboxylic acid derivatives useful as inhibitors of Flaviviridae viruses
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
WO2013016492A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Thiophene compounds
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DE112012002748T5 (de) 2011-10-21 2014-07-31 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
CN103087052A (zh) * 2011-10-31 2013-05-08 上海壹志医药科技有限公司 噻吩衍生物及其药物用途
WO2014055142A1 (en) * 2012-06-20 2014-04-10 Cocrystal Discovery, Inc. Inhibitors of hepatitis c virus polymerase
US8841340B2 (en) 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
US8759544B2 (en) 2012-08-17 2014-06-24 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8927741B2 (en) 2012-08-17 2015-01-06 Gilead Sciences, Inc. Synthesis of an antiviral compound
EP2762124A1 (en) 2013-01-31 2014-08-06 IP Gesellschaft für Management mbH Packaging comprising administration units of polymorphs, amorphous forms or solvates
TWI731854B (zh) 2015-03-23 2021-07-01 美商共結晶製藥公司 Ｃ型肝炎病毒聚合酶之抑制劑
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
MX2020011912A (es) 2018-05-09 2021-01-29 Cocrystal Pharma Inc Terapia de combinacion para el tratamiento del virus de la hepatitis c (vhc).

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3076817A (en) * 1963-02-05 New j-amino-thiophene-z
DE1055007B (de) 1957-08-29 1959-04-16 Dr Hans Fiesselmann Verfahren zur Herstellung von 3-Aminothiophen-2-carbonsaeureestern und den entsprechenden freien Carbonsaeuren
US3470151A (en) * 1966-05-17 1969-09-30 Beecham Group Ltd Furyl- and thienyl-penicillins and salts thereof
AU518216B2 (en) * 1977-09-06 1981-09-17 Hafslund Nycomed Pharma Aktiengesellschaft Thienothiazine derivatives
US4244205A (en) 1978-04-25 1981-01-13 Wean United Inc. Apparatus for aligning extrusion producing members of a press
DD146952A1 (de) 1979-11-09 1981-03-11 Karl Gewald Verfahren zur herstellung von substituierten 3-amino-4-cyan-5-phenylthiophenen
JPS57116077A (en) 1981-01-12 1982-07-19 Kanebo Ltd Thieno(3,2-b)pyridinecarboxylic acid derivative
GB8515207D0 (en) * 1985-06-15 1985-07-17 Boots Co Plc Therapeutic agents
GB8627698D0 (en) 1986-11-20 1986-12-17 Boots Co Plc Therapeutic agents
DD263055A1 (de) 1987-07-28 1988-12-21 Univ Dresden Tech Verfahren zur herstellung substituierter 3-amino-5-phenyl-thiophene
DE4023048A1 (de) * 1990-07-20 1992-01-23 Basf Ag Dicarbonsaeureimide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
JP2574085B2 (ja) 1991-10-28 1997-01-22 株式会社トクヤマ ３−アミノ−２−チオフェンカルボン酸誘導体の製造方法
FR2689129B1 (fr) 1992-03-27 1995-05-12 Atochem Elf Sa Nouveaux dérivés de l'acide 3-mercapto-2-thénoique et leurs procédés de préparation.
JPH0625221A (ja) 1992-07-10 1994-02-01 Tokuyama Soda Co Ltd ３−アミノ−２−チオフェンカルボン酸誘導体の製造方法
JPH0748360A (ja) 1993-05-31 1995-02-21 Yoshitomi Pharmaceut Ind Ltd ビフェニルテトラゾール誘導体
EP0658559A1 (de) * 1993-12-14 1995-06-21 Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. Thienothiazinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als 5-dipoxygenase und Cyclooxygenaseinhibitoren
DE19522603A1 (de) * 1995-06-19 1997-01-09 Siemens Ag Schutzeinrichtung gegen Überlastung der Schaltkontakte eines Schaltgerätes
KR100423590B1 (ko) * 1995-08-02 2004-09-10 호따. 우리아치에씨아. 에세. 아. 항진균활성을갖는신규피리미돈유도체
BR9606546A (pt) * 1995-08-02 1998-07-14 Uriach & Cia Sa J Novas carboxamidas com atividade fungicida
AP1019A (en) 1996-10-18 2001-10-16 Vertex Pharma Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease.
JP4000608B2 (ja) * 1996-11-07 2007-10-31 トヨタ自動車株式会社 水素製造充填装置および電気自動車
TW523506B (en) * 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
AP9901643A0 (en) * 1997-04-28 1999-10-02 Texas Biotechnology Corp Sulfonamides for treatment of endothelin-mediated disorders.
US5783705A (en) * 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
US6187799B1 (en) * 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US6344476B1 (en) * 1997-05-23 2002-02-05 Bayer Corporation Inhibition of p38 kinase activity by aryl ureas
ES2241157T3 (es) 1997-08-11 2005-10-16 Boehringer Ingelheim (Canada) Ltd. Peptidos inhibidores de la hepatitis c.
EP1012180B1 (en) 1997-08-11 2004-12-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
DE69816102D1 (de) * 1997-09-02 2003-08-07 Mitsubishi Pharma Corp Kondensierte thiophenderivate und ihre medizinische anwendung
US6140351A (en) * 1997-12-19 2000-10-31 Berlex Laboratories, Inc. Ortho-anthranilamide derivatives as anti-coagulants
US7329670B1 (en) * 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
AU2003204708B2 (en) 1997-12-22 2006-05-25 Bayer Healthcare Llc Inhibition of Raf Kinase using Substituted Heterocyclic Ureas
US6291514B1 (en) * 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
US20050119332A1 (en) * 1998-03-12 2005-06-02 Lone Jeppesen Substituted thiophene compounds as modulators of protein tyrosine phosphatases (PTPases)
US6262044B1 (en) * 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
US6214879B1 (en) * 1998-03-24 2001-04-10 Virginia Commonwealth University Allosteric inhibitors of pyruvate kinase
US6689754B1 (en) * 1998-04-10 2004-02-10 G. D. Searle & Co. Heterocyclic glycyl β-alanine derivatives
ATE228119T1 (de) * 1998-04-15 2002-12-15 Pfizer Prod Inc Heterocyclische carboxamide
EP0960882A1 (en) * 1998-05-19 1999-12-01 Hoechst Marion Roussel Deutschland GmbH Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
US6858223B2 (en) * 1998-06-23 2005-02-22 Altana Pharma Ag Compositions comprising phenylaminothiophenacetic acid derivatives for the treatment of acute or adult respiratory distress syndrome (ARDS) and infant respiratory distress syndrome (IRDS)
AU4385399A (en) * 1998-06-29 2000-01-17 Biochem Pharma Inc. Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer
AU756627B2 (en) 1998-07-27 2003-01-16 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Diketoacid-derivatives as inhibitors of polymerases
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US7101878B1 (en) * 1998-08-20 2006-09-05 Agouron Pharmaceuticals, Inc. Non-peptide GNRH agents, methods and intermediates for their preparation
DE19903398A1 (de) 1999-01-29 2000-08-10 Hassan Jomaa Verwendung von Thiadiazolderivaten zur prophylaktischen und therapeutischen Behandlung von Infektionen
EP1152759A2 (en) * 1999-02-09 2001-11-14 3-Dimensional Pharmaceuticals, Inc. METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR
NZ528846A (en) * 1999-03-12 2005-05-27 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
WO2000055152A1 (en) * 1999-03-12 2000-09-21 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
JP2001010957A (ja) 1999-04-28 2001-01-16 Sankyo Co Ltd 肝障害の予防または抑制剤
DE19920247A1 (de) 1999-05-03 2000-11-16 Hassan Jomaa Arzneimittel mit einem Gehalt an Verbindungen mit einem Stickstoff-Sauerstoff-Heterocyclus als Wirkstoff und ihre Verwendung
HN2000000051A (es) * 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
US6867217B1 (en) * 1999-05-19 2005-03-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
GB9929552D0 (en) * 1999-12-14 2000-02-09 Proteus Molecular Design Compounds
CA2385972A1 (en) 1999-10-01 2001-04-12 Haruhisa Ogita Novel diarylamide derivatives and use thereof as medicines
KR20020058046A (ko) * 1999-11-29 2002-07-12 한스 루돌프 하우스, 헨리테 브룬너, 베아트리체 귄터 살충성 ｎ-헤테로아릴 알파-알콕시미노-카르복사미드
EP1162196A4 (en) 1999-12-27 2003-04-16 Japan Tobacco Inc COMPOUNDS WITH JOINED CYCLES AND THEIR USE AS MEDICAMENTS
DE10002424A1 (de) * 2000-01-20 2001-07-26 Siemens Ag Di(het)arylaminothiophen-Derivate
GB0003154D0 (en) * 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
MY138097A (en) * 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
US20040034041A1 (en) 2000-05-10 2004-02-19 Dashyant Dhanak Novel anti-infectives
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
JP2001354658A (ja) 2000-06-15 2001-12-25 Taisho Pharmaceut Co Ltd ヒドロキシホルムアミジン化合物及びその塩並びにそれらを含む医薬
US6414013B1 (en) * 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
ES2271109T3 (es) * 2000-11-08 2007-04-16 Syngenta Participations Ag Pirrocarboxamidas y pirrolcarbotioamidas y sus usos agroquimicos.
ES2263687T3 (es) 2000-11-20 2006-12-16 Bristol-Myers Squibb Company Inhibidores tripeptidicos de la hepatitis c.
US7015223B1 (en) * 2000-11-20 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade
US6892279B2 (en) * 2000-11-30 2005-05-10 Mosaid Technologies Incorporated Method and apparatus for accelerating retrieval of data from a memory system with cache by reducing latency
DE10061876A1 (de) * 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
WO2002057425A2 (en) 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
DE60239097D1 (de) 2001-03-02 2011-03-17 Gpc Biotech Ag Drei-hybrid-assaysystem
US20040102324A1 (en) * 2002-02-28 2004-05-27 Annis Gary David Heterocyclic diamide invertebrate pest control agents
AU2002252183A1 (en) 2001-03-06 2002-09-19 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
US6734207B2 (en) * 2001-04-20 2004-05-11 Parker Hughes Institute Cytotoxic compounds
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
US6713638B2 (en) * 2001-05-18 2004-03-30 Joel M. Linden 2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
US6887877B2 (en) * 2001-06-11 2005-05-03 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
CN101624391A (zh) * 2001-06-11 2010-01-13 病毒化学医药公司 用作黄病毒感染抗病毒剂的噻吩衍生物
SE0102102D0 (sv) * 2001-06-13 2001-06-13 Hoeganaes Ab High density stainless steel products and method for the preparation thereof
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
SE0102617D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
US6689854B2 (en) 2001-08-23 2004-02-10 3M Innovative Properties Company Water and oil repellent masonry treatments
JP2003073357A (ja) 2001-09-03 2003-03-12 Mitsubishi Pharma Corp アミド化合物を含有するＲｈｏキナーゼ阻害剤
US6924276B2 (en) * 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
WO2003026587A2 (en) 2001-09-26 2003-04-03 Bristol-Myers Squibb Company Compounds useful for treating hepatitus c virus
DE60229975D1 (de) * 2001-10-04 2009-01-02 Smithkline Beecham Corp Nf-kb-inhibitoren
US7285557B2 (en) * 2001-10-15 2007-10-23 Smithkline Beecham P.L.C. Pyrimidinones as melanin concentrating hormone receptor 1
US7220777B2 (en) * 2001-10-15 2007-05-22 Smithkline Beecham P.L.C. Lactam derivatives as antagonists for human 11cby receptors
AU2002348414B2 (en) 2001-10-24 2009-10-01 Vertex Pharmaceuticals Incorporated Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system
TWI281916B (en) * 2001-10-25 2007-06-01 Lilly Co Eli Antitumor compounds and methods
WO2003055479A1 (en) * 2001-12-21 2003-07-10 Consejo Superior De Investigaciones Cientificas Compounds and their therapeutic use related to the phosphorylating activity of the enzyme gsk-3
US6835745B2 (en) * 2002-01-15 2004-12-28 Wyeth Phenyl substituted thiophenes as estrogenic agents
US20040023961A1 (en) * 2002-02-11 2004-02-05 Bayer Corporation Aryl ureas with raf kinase and angiogenisis inhibiting activity
AU2003223602B8 (en) 2002-04-11 2010-05-27 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis C virus NS3-NS4 protease
HRP20041220A2 (hr) * 2002-05-28 2006-04-30 3-Dimensional Pharmaceuticals Novi tiofen amidini, njihovi pripravci i postupci liječenja komplementom posredovanih bolesti i stanja
CN1155679C (zh) 2002-09-20 2004-06-30 华南理工大学 含低聚噻吩骨格的液晶化合物及其制备方法
US7179836B2 (en) * 2002-09-20 2007-02-20 Smithkline Beecham Corporation Chemical compounds
US7902203B2 (en) * 2002-11-01 2011-03-08 Abbott Laboratories, Inc. Anti-infective agents
US20050075331A1 (en) * 2003-10-06 2005-04-07 Pratt John K. Anti-infective agents
US20040162285A1 (en) * 2002-11-01 2004-08-19 Pratt John K. Anti-infective agents
US20040097492A1 (en) * 2002-11-01 2004-05-20 Pratt John K Anti-infective agents
EP2361913A1 (en) 2002-11-01 2011-08-31 Abbott Laboratories Anti-infective agents
DE10253220A1 (de) * 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
JP4926403B2 (ja) * 2002-12-10 2012-05-09 ヴァイロケム ファーマ インコーポレイテッド フラビウイルス感染の処置もしくは予防のための化合物および方法
AU2003291886A1 (en) 2002-12-10 2004-06-30 Virochem Pharma Inc. Thiophenederivatives for the treatment of flavivirus infections
US7402608B2 (en) 2002-12-10 2008-07-22 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
US7098241B2 (en) * 2002-12-16 2006-08-29 Hoffmann-La Roche Inc. Thiophene hydroxamic acid derivatives
US7196114B2 (en) * 2003-02-17 2007-03-27 Sanofi-Aventis Deutschland Gmbh Substituted 3-(benzoylureido) thiophene derivatives, processes for preparing them and their use
EP1636208B1 (en) 2003-04-11 2012-02-29 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2004092161A1 (en) 2003-04-11 2004-10-28 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
EP1646642A2 (en) 2003-07-18 2006-04-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
UY28500A1 (es) 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
WO2005028502A1 (en) 2003-09-18 2005-03-31 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
TW200512181A (en) * 2003-09-26 2005-04-01 Tanabe Seiyaku Co Amide-type carboxamide derivatives
DE10359791A1 (de) * 2003-12-19 2005-07-21 Bayer Healthcare Ag Substituierte Thiophene
WO2005077969A2 (en) 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
JP2007530516A (ja) * 2004-03-26 2007-11-01 スミスクライン・ビーチャム・コーポレイション 抗ウイルス剤として有用な４−カルボキシピラゾール誘導体
MXPA06010520A (es) * 2004-03-30 2007-03-26 Chiron Corp Derivados de tiofeno sustituidos como agentes anticancerosos.
EP1771169A1 (en) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
RU2007116265A (ru) 2004-10-01 2008-11-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибирование протеазы ns3-ns4a вируса hcv
DE102004061746A1 (de) * 2004-12-22 2006-07-06 Bayer Healthcare Ag Alkinyl-substituierte Thiophene
DE102005028077A1 (de) 2004-12-22 2006-07-13 Aicuris Gmbh & Co. Kg Alkinyl-substituierte Thiophene
BRPI0610283A2 (pt) 2005-05-13 2010-10-19 Virochem Pharma Inc composto, uso do mesmo na preparação de um medicamento para o tratamento ou prevenção de uma infecção por vìrus de hepatite c, composição farmacêutica e combinação farmacêutica
US20100160255A1 (en) * 2005-07-29 2010-06-24 Takeda Pharmaceutical Company Limited Spiro-cyclic compound

Also Published As

Publication number Publication date
IL198751A0 (en) 2010-02-17
ECSP099319A (es) 2009-07-31
NZ576780A (en) 2011-12-22
CA2670260A1 (en) 2008-05-22
NO20092038L (no) 2009-08-10
US8269014B2 (en) 2012-09-18
SI2104674T1 (sl) 2013-09-30
CN101568538A (zh) 2009-10-28
US20120301430A1 (en) 2012-11-29
SG176488A1 (en) 2011-12-29
NZ596922A (en) 2013-03-28
US20080299080A1 (en) 2008-12-04
WO2008058393A1 (en) 2008-05-22
BRPI0718915A2 (pt) 2013-12-03
AP2009004859A0 (en) 2009-06-30
DK2104674T3 (da) 2013-07-15
EP2104674B8 (en) 2013-10-02
HRP20130658T1 (en) 2013-09-30
AU2007321677B2 (en) 2013-04-11
AP2579A (en) 2013-01-29
ES2423219T3 (es) 2013-09-18
HK1136562A1 (en) 2010-07-02
CN102250074A (zh) 2011-11-23
EP2104674A4 (en) 2010-03-17
HK1138569A1 (en) 2010-08-27
EP2559692A1 (en) 2013-02-20
PT2104674E (pt) 2013-07-26
JP2012006966A (ja) 2012-01-12
US8003685B2 (en) 2011-08-23
CN101568538B (zh) 2012-09-05
EA201101492A1 (ru) 2012-09-28
KR20090086081A (ko) 2009-08-10
MX2009005185A (es) 2009-07-07
CO6180430A2 (es) 2010-07-19
US20120059170A1 (en) 2012-03-08
RS52874B (sr) 2013-12-31
CN102675279A (zh) 2012-09-19
JP5290186B2 (ja) 2013-09-18
JP2010509376A (ja) 2010-03-25
US8658674B2 (en) 2014-02-25
AU2007321677A1 (en) 2008-05-22
EP2104674B1 (en) 2013-05-01
EP2104674A1 (en) 2009-09-30
EA016457B1 (ru) 2012-05-30
EA200970478A1 (ru) 2009-12-30
EP2559691A1 (en) 2013-02-20

Similar Documents

Publication Publication Date Title
AP2579A (en) Thiophene analogues for the treatment or prevention of flavivirus infections
ZA201204625B (en) Analogues for the treatment or prevention of flavivirus infections
ZA200709727B (en) Compounds and methods for the treatment of prevention of flavivirus infections
IL217503A0 (en) Benzimidazole analogues for the treatment or prevention of flavivirus infections
SI2079760T1 (sl) Sestavki in metode za zdravljenje okužb
AP2011005901A0 (en) Thienopyridine derivatives for the treatment and prevention of dengue virus infections.
IL187999A0 (en) Compositions for the treatment of persistent infections
IL194506A0 (en) Implants for the treatment of dopamine associated states
IL195272A0 (en) Methods and compositions for the treatment of viral infections
GB0909297D0 (en) Composition for the treatment of skin conditions
PL2111855T3 (pl) Kompozycje przeciwbakteryjne do leczenia infekcji górnych i dolnych dróg oddechowych
IL197766A0 (en) Use of oritavancin for the prevention and treatment of anthrax
EP2056830A4 (en) SPECIAL COMPOSITIONS FOR TREATMENT OR PREVENTION OF METABOLIC SYNDROME
ZA200806505B (en) Treatment of HIV
GB0602857D0 (en) The treatment of sialorrhoea
IL176303A0 (en) Pharmaceutical composition for the treatment of otomycosis
GB0624439D0 (en) Technique for treatment of gall-and kidney-stones
GB0602858D0 (en) The treatment of sialorrhoea
GB0602855D0 (en) The Treatment Of Sialorrhoea
PL1996207T3 (pl) Kompozycje zawierające chitozan przydatne do kompleksowego leczenia terapeutycznego lub kompleksowej profilaktyki zespołu metabolicznego
GB0609792D0 (en) The treatment of multiple sclerosis
HK1181051A (en) Analogues for the treatment or prevention of flavivirus infections
GB0625602D0 (en) Treatment of sialorrhoea
GB0601091D0 (en) The Treatment Of Ocular Conditions
IL197485A0 (en) Use of vitamin d compounds for the prevention of adhesions